Table 5 The hybridization and combination of cancer nanomedicine
Targeting strategy | Stimuli-responsiveness | Therapeutic agent | Tumor type | Refs |
|---|---|---|---|---|
FA | pH | PEG-FA/(DOX + VER)@ZIF-8 | Melanoma | [522] |
GSH | FA-S–S-PLGA NPs | Lung cancer | [523] | |
ROS | Lut/FA-Oxi-αCD NPs | Breast cancer | [524] | |
MMP2 | F/TMSP-NLC | Fibrosarcoma | [525] | |
pH and GSH | PsEEL-DOX/PTX NMs | Lung cancer | [403] | |
pH and ROS | DT-NP | Breast cancer | [527] | |
pH and laser | HM-Bi@PEG-FA NSs | Lung cancer | [528] | |
HA | GSH | HL/MOS@M780&LOD NPs | Breast cancer | [526] |
pH | HA/(R837 + 1 MT)@ZIF-8 | Melanoma | [529] | |
Laser | DOX/ICG-CuS@MnO2/HA NPs | Breast cancer | [530] | |
pH and GSH | DOX/siGCN5@HPMSNs | Breast cancer | [531] | |
GSH and hypoxia | PaHAsC | Melanoma | [91] | |
RGD | GSH | RGD/MoS2/DOX | Cervical cancer | [532] |
pH | Met/GOx@His/ZIF-8∼RGD | Breast cancer | [533] | |
MMP-2 | RHMH18@AuD NPs | Ovarian cancer | [534] | |
Laser | SPIOCs@HSA(PTX)-RGD | Glioma | [535] | |
pH and esterase | IR825@IRI-ATRA/RGD NPs | Breast cancer | [536] | |
pH and GSH | CuS DENPs | Breast cancer | [537] | |
Biotin | pH | B780/Qu NPs | Breast cancer | [98] |
GSH | SS-biotin-Ppy NWs | Breast cancer | [538] | |
Transferrin | Temperature | TMNP | Breast cancer | [80] |
GSH | DMSN@PMAsh-Tf | Lung cancer | [539] | |
pH/temperature | LF-PNIPAM-co-AA | Breast cancer | [540] | |
LHRH | GSH | PTX-LHRH-DCMs | Breast cancer | [97] |
pH, HIFU, and ultrasound | LHRH-ELP-DOX | Breast cancer | [541] | |
EPR effects | pH and cathepsin B | TNV | Melanoma and colon cancer | [250] |
P2, pH and ROS | SRF/Ce6-loaded PEG-M-PPMT NPs | Lung cancer | [542] | |
RGD and EPR effects | Laser and GSH | RDG/shRNA | Breast cancer | [543] |